Tin tức & Cập nhật

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.

Young adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who drink alcoholic beverages are at greater risk of mortality and of having an unhealthy liver, reports a study presented at AASLD 2024.

Microvascular invasion and/or satellitosis (mVI/S) is independently associated with aggressive recurrence and mortality in hepatocellular carcinoma (HCC) patients treated with liver resection (LR), a recent study has shown.

Even modest alcohol consumption is associated with a higher risk of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study.

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at greater risk of developing incident hepatocellular carcinoma (HCC) when factors such as smoking, alcohol use, obesity, diabetes, and hypertension are present, according to a study. However, use of statin, metformin, or aspirin may modify disease progression.

The oral fatty acid synthase (FASN) inhibitor denifanstat appears to produce meaningful improvements in metabolic dysfunction-associated steatohepatitis (MASH) and stage 2–3 fibrosis, as shown in the results of a phase IIb trial.

Treatment with survodutide, which has previously shown its efficacy in reducing body weight and glycaemia in people with obesity or type 2 diabetes, is well tolerated by patients with compensated or decompensated cirrhosis, reports a study.

Patients with cirrhosis with iron deficiency anemia after variceal bleed (VB) can rely on the efficacy and safety of intravenous (IV) iron replacement, reports a study.